RecruitingPhase 2NCT06557733
Rare condition
Familial adenomatous polyposis
18
studies recruiting now
as of 7 Sept 2026
100
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
24 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingNot applicableNCT07726771
Evaluation of the Ileo-anal Pouch in FAP (ENDOPOL)
RecruitingNCT02012699
Integrated Cancer Repository for Cancer Research
RecruitingNot applicableNCT07066046
Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 18 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Familial adenomatous polyposis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Familial adenomatous polyposis
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
1 approved treatment and 15 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Celecoxib (Celebra)
Phase 3Metformin
Phase 3Eflornithine, (S)-
Phase 3Calcitriol (Calcijex)
Phase 3Icosapent
Phase 3Sulindac (Clinoril)
Phase 3Aspirin (8-hour bayer)
Phase 3Calcium Carbonate (Adcal)
Phase 3Eflornithine
+ 7 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).